Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2013.04.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade.
BMC Rheumatol
January 2025
Department of Rheumatology, Overton Brooks VA Medical Center, Shreveport, LA, USA.
Background: Dermatomyositis is a chronic inflammatory condition affecting muscles and skin, often associated with an increased risk of cancer. Specific autoantibodies, including anti-TIF1 (Transcription Intermediary Factor 1), have been linked to this risk. We present a case of dermatomyositis in a male patient positive for anti-TIF1 antibodies, subsequently diagnosed with squamous cell carcinoma of the tonsil, a novel association not previously documented.
View Article and Find Full Text PDFEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Demographic and clinicopathological comparison among oral lichen planus, lichenoid lesions and proliferative verrucous leukoplakia: a retrospective study.
BMC Oral Health
December 2024
Dental Sciences Graduate Program. Federal University of Espirito Santo (UFES), Avenida Maruípe 1468, Maruípe, Vitória, 29040-090, ES, Brazil.
Article Synopsis
- The study focused on comparing oral lichen planus and related lesions due to their risk of becoming cancerous and the need to differentiate them from similar conditions.
- Researchers conducted a survey among patients to collect sociodemographic and clinical data, analyzing this information using statistical tests.
- The findings revealed distinct characteristics for each type of lesion, with lichen planus showing reticular patterns and the buccal mucosa being the most affected area, while proliferative verrucous leukoplakia was linked with significant epithelial dysplasia.
Secondary Myiasis in an Immunocompetent Patient With Severe Chromoblastomycosis.
Cureus
October 2024
Family Medicine, St. Joseph's Regional Medical Center, Paterson, USA.
This is the case of chronic chromoblastomycosis (CBM) in a 61-year-old male from the Dominican Republic (DR) with extensive cutaneous eruptions over multiple areas of the body including bilateral lower extremities and the flank extending to the back. A 61-year-old male with a history of morbid obesity, chronic kidney disease stage III, and well-controlled hypertension presented to the family medicine clinic for the evaluation of chronic painful skin lesions on his legs and torso. The lesions began 19 years prior, following a flood in the Dominican Republic (DR) where he was living at the time.
View Article and Find Full Text PDFEvaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review.
J Cutan Med Surg
November 2024
Cancer Research Program, McGill University Health Centre Research Institute, Montreal, QC, Canada.
Article Synopsis
- Recent FDA approval of difluoromethylornithine (DFMO) has sparked interest in its potential for preventing various cancers, including keratinocyte carcinomas (KCs), beyond its initial purpose for neuroblastoma in children.
- A systematic review of 12 studies involving 1,618 predominantly Caucasian patients revealed mixed results, with oral DFMO showing a significant reduction in KCs in only 24% of cases, while topical DFMO showed modest effectiveness in reducing actinic keratosis.
- Overall, the current evidence does not strongly support the use of oral DFMO, whereas topical DFMO may offer a better option for certain patients in preventing skin cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!